Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders
Moldiag Diseases Genes Support Contact

Oncogene NRAS

The NRAS gene encodes a membrane protein that shuttles proteins from Golgi apparatus to the plasma membrane. Germline mutations cause autosomal dominant Noonan syndrome 6 and somatic mutation are observed in several tumors.

Genetests:

Clinic Method Carrier testing
Turnaround 5 days
Specimen type genomic DNA
Clinic Method Massive parallel sequencing
Turnaround 25 days
Specimen type genomic DNA
Research Method Genomic sequencing of the entire coding region
Turnaround 25 days
Specimen type genomic DNA
Research Method Multiplex Ligation-Dependent Probe Amplification
Turnaround 25 days
Specimen type genomic DNA

Related Diseases:

Follicular thyroid carcinoma
HRAS
NRAS
Noonan syndrome 6
TRHR

References:

1.

Oliveira JB et al. (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome.

external link
2.

Rabin M et al. (1984) NRAS transforming gene maps to region p11----p13 on chromosome 1 by in situ hybridization.

external link
3.

Mitchell EL et al. (1995) Determination of the gene order of the three loci CD2, NGFB, and NRAS at human chromosome band 1p13 and refinement of their localisation at the subband level by fluorescence in situ hybridisation.

external link
4.

Bezieau S et al. (2001) High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.

external link
5.

Matallanas D et al. (2003) Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization.

external link
6.

Vasko V et al. (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors.

external link
7.

Rocks O et al. (2005) An acylation cycle regulates localization and activity of palmitoylated Ras isoforms.

external link
8.

Johnson SM et al. (2005) RAS is regulated by the let-7 microRNA family.

external link
9.

Takahashi C et al. (2006) Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor.

external link
10.

Miller CA et al. (2013) Genomic landscapes and clonality of de novo AML.

external link
11.

Haigis KM et al. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

external link
12.

Dessars B et al. (2009) Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis.

external link
13.

Niemela JE et al. (2011) Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.

external link
14.

Nazarian R et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

external link
15.

Hafner C et al. (2012) Keratinocytic epidermal nevi are associated with mosaic RAS mutations.

external link
16.

Kinsler VA et al. (2013) Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.

external link
17.

Lim YH et al. (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.

external link
18.

Li Q et al. (2013) Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

external link
19.

Taparowsky E et al. (1983) Structure and activation of the human N-ras gene.

external link
20.

et al. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

external link
21.

Brewin J et al. (2013) Genomic landscapes and clonality of de novo AML.

external link
22.

Nikiforova MN et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

external link
23.

Matsuda K et al. (2007) Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.

external link
24.

De Filippi P et al. (2009) Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.

external link
25.

Cirstea IC et al. (2010) A restricted spectrum of NRAS mutations causes Noonan syndrome.

external link
26.

Dracopoli NC et al. (1990) Mapping the human amylase gene cluster on the proximal short arm of chromosome 1 using a highly informative (CA)n repeat.

external link
27.

Lübbert M et al. (1990) N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis.

external link
28.

Hall A et al. (1985) Human N-ras: cDNA cloning and gene structure.

external link
29.

Nitta N et al. (1987) Amino-acid substitution at codon 13 of the N-ras oncogene in rectal cancer in a Japanese patient.

external link
30.

Popescu NC et al. (1985) Chromosomal localization of three human ras genes by in situ molecular hybridization.

external link
31.

Povey S et al. (1985) Report of the Committee on the Genetic Constitution of Chromosomes 1 and 2.

external link
32.

Münke M et al. (1984) Comparative analysis of mouse-human hybrids with rearranged chromosomes 1 by in situ hybridization and Southern blotting: high-resolution mapping of NRAS, NGFB, and AMY on human chromosome 1.

external link
33.

Marshall CJ et al. (1982) A transforming gene present in human sarcoma cell lines.

external link
34.

Ryan J et al. (1983) Chromosomal assignment of a family of human oncogenes.

external link
35.

Yuasa Y et al. (1984) Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells.

external link
36.

Davis M et al. (1983) Localisation of the human N-ras oncogene to chromosome 1cen - p21 by in situ hybridisation.

external link
37.

Orphanet article

Orphanet ID 221346 external link
38.

NCBI article

NCBI 4893 external link
39.

OMIM.ORG article

Omim 164790 external link
40.

Wikipedia article

Wikipedia EN (Neuroblastoma_RAS_viral_oncogene_homolog) external link
Update: Aug. 14, 2020
Copyright © 2005-2020 by Center for Nephrology and Metabolic Disorders, Dr. Mato Nagel, MD
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Germany, Tel.: +49-3576-287922, Fax: +49-3576-287944
Sitemap | Webmail | Disclaimer | Privacy Issues